Brief: Mesoblast Says Ryoncil Shows 84% Survival Rate In Children With Sr-Agvhd
26/01/2026 23:48
Jan 26 (Reuters) - Mesoblast Ltd MSB.AX: MESOBLAST LTD - RYONCIL SHOWS 84% SURVIVAL RATE IN CHILDREN WITH SR-AGVHD Source text: ID:nGNX7tzB2c Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil